Chapter 25 – HORMONES OF THE CARDIOVASCULAR SYSTEM

Neurohormonal systems play a critical role in cardiovascular homeostasis as well cardiovascular pathophysiology and diseases such as congestive heart failure, coronary artery disease, hypertension and chronic kidney disease. Neurohormonal activation is an important cause and therefore an important therapeutic target to treat cardiovascular diseases. It is well established that activation of hormonal systems such as the renin-angiotensin-aldosterone system leads to increased cardiac injury and dysfunction which predispose to congestive heart failure. Obesity is also associated with neurohormonal activation and it is associated with multiple hemodynamic and metabolic factors which increase the risk of developing cardiovascular and renal diseases. In addition to direct hemodynamic effects, activation of hormonal systems may cause cardiovascular dysfunction through mechanisms including inflammation, oxidative stress, and mitochondrial dysfunction. In this chapter we briefly discuss the hemodynamic effects of several key cardiovascular hormones as well as their nonhemodynamic effects with a focus on inflammation, oxidative stress, and metabolic regulation.

[1]  J. Dyck,et al.  Is AMPK the savior of the failing heart? , 2015, Trends in Endocrinology & Metabolism.

[2]  K. Channon,et al.  Adiponectin as a Link Between Type 2 Diabetes and Vascular NADPH Oxidase Activity in the Human Arterial Wall: The Regulatory Role of Perivascular Adipose Tissue , 2014, Diabetes.

[3]  K. Bailey,et al.  Endothelial function in women of the Kronos Early Estrogen Prevention Study , 2014, Climacteric : the journal of the International Menopause Society.

[4]  M. Blüher,et al.  Adipocyte dysfunction, inflammation and metabolic syndrome , 2014, Reviews in Endocrine and Metabolic Disorders.

[5]  Deepak L. Bhatt,et al.  Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. , 2014, Journal of the American College of Cardiology.

[6]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[7]  Michael E. Hall,et al.  Rescue of cardiac leptin receptors in db/db mice prevents myocardial triglyceride accumulation. , 2014, American journal of physiology. Endocrinology and metabolism.

[8]  C. Hamm,et al.  INFLUENCE OF RENAL SYMPATHETIC DENERVATION ON VASCULAR INFLAMMATION IN ESSENTIAL HYPERTENSION , 2014 .

[9]  A. Brett.  Catheter-Based Renal Denervation for Resistant Hypertension , 2014 .

[10]  R. Kacker,et al.  Deaths and cardiovascular events in men receiving testosterone. , 2014, JAMA.

[11]  P. Raggi,et al.  Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. , 2014, Atherosclerosis.

[12]  G. Grunwald,et al.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.

[13]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[14]  J. Goodwin,et al.  Trends in androgen prescribing in the United States, 2001 to 2011. , 2013, JAMA internal medicine.

[15]  A. Serpa Neto,et al.  Spontaneous breathing trial reduces mechanical ventilation weaning when compared with SmartCare™ ventilation , 2013, Critical Care.

[16]  Guido Grassi.  Renal denervation in cardiometabolic disease: concepts, achievements and perspectives. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[17]  Michael E. Hall,et al.  Cardiomyocyte-specific deletion of leptin receptors causes lethal heart failure in Cre-recombinase-mediated cardiotoxicity. , 2012, American journal of physiology. Regulatory, integrative and comparative physiology.

[18]  C. O'Donnell,et al.  Restoration of glucose metabolism in leptin-resistant mouse hearts after acute myocardial infarction through the activation of survival kinase pathways. , 2012, Journal of molecular and cellular cardiology.

[19]  Faloia Emanuela,et al.  Inflammation as a Link between Obesity and Metabolic Syndrome , 2012, Journal of nutrition and metabolism.

[20]  G. Bakris,et al.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. , 2012, Journal of the American Society of Hypertension : JASH.

[21]  F. Sam,et al.  Adiponectin in Cardiovascular Inflammation and Obesity , 2011, International journal of inflammation.

[22]  C. Torp‐Pedersen,et al.  Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. , 2011, Journal of the American College of Cardiology.

[23]  H. Krum,et al.  Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.

[24]  Michael Böhm,et al.  Renal denervation: a potential new treatment modality for polycystic ovary syndrome? , 2011, Journal of hypertension.

[25]  M. Razzaque,et al.  The dualistic role of vitamin D in vascular calcifications. , 2011, Kidney international.

[26]  M. Zile,et al.  Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. , 2011, Journal of cardiac failure.

[27]  P. Libby,et al.  Deletion of EP4 on Bone Marrow–Derived Cells Enhances Inflammation and Angiotensin II–Induced Abdominal Aortic Aneurysm Formation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[28]  C. Koch,et al.  Testosterone Deficiency as a Risk Factor for Cardiovascular Disease , 2011, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  S. Adler,et al.  The Renin Inhibitor Aliskiren Attenuates High-Glucose Induced Extracellular Matrix Synthesis and Prevents Apoptosis in Cultured Podocytes , 2011, Nephron Experimental Nephrology.

[30]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[31]  M. Azarpazhooh,et al.  Simvastatin Therapy Reduces Prooxidant-Antioxidant Balance: Results of a Placebo-Controlled Cross-Over Trial , 2011, Lipids.

[32]  M. Prins,et al.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.

[33]  H. Krum,et al.  Meta-analysis: Effect of B-Type Natriuretic Peptide Testing on Clinical Outcomes in Patients With Acute Dyspnea in the Emergency Setting , 2010, Annals of Internal Medicine.

[34]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[35]  Y. Bobryshev.  Vitamin D3 suppresses immune reactions in atherosclerosis, affecting regulatory T cells and dendritic cell function. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[36]  Cornelia Weikert,et al.  Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[37]  Katsuya Iijima,et al.  Induction of Endothelial Nitric Oxide Synthase, SIRT1, and Catalase by Statins Inhibits Endothelial Senescence Through the Akt Pathway , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[38]  R. Goyal,et al.  Is hypoandrogenemia a component of metabolic syndrome in males? , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[39]  S. Hwang,et al.  Inhibition of the Soluble Epoxide Hydrolase Promotes Albuminuria in Mice with Progressive Renal Disease , 2010, PloS one.

[40]  P. Libby,et al.  Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). , 2010, The American journal of cardiology.

[41]  G. Ewy,et al.  Epinephrine in resuscitation: curse or cure? , 2010, Future cardiology.

[42]  J. Manson,et al.  Postmenopausal hormone therapy: an Endocrine Society scientific statement. , 2010, The Journal of clinical endocrinology and metabolism.

[43]  K. Swedberg,et al.  Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. , 2010, European heart journal.

[44]  R. Carey,et al.  Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease , 2010, American Journal of Nephrology.

[45]  A. Daugherty,et al.  Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE−/− mice , 2010, Clinical science.

[46]  C. Frampton,et al.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.

[47]  C. A. Koch,et al.  Does Vitamin D Deficiency Cause Hypertension? Current Evidence from Clinical Studies and Potential Mechanisms , 2009, International journal of endocrinology.

[48]  A. Mihailidou,et al.  Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology , 2009, Molecular and Cellular Endocrinology.

[49]  T. Murohara,et al.  Adiponectin and cardiovascular disease. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[50]  Lie Gao,et al.  Imbalance of Angiotensin Type 1 Receptor and Angiotensin II Type 2 Receptor in the Rostral Ventrolateral Medulla: Potential Mechanism for Sympathetic Overactivity in Heart Failure , 2008, HYPERTENSION.

[51]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[52]  S. Solomon,et al.  Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.

[53]  A. Guillouzo,et al.  Catecholamines induce an inflammatory response in human hepatocytes , 2008, Critical care medicine.

[54]  H. Matsubara,et al.  Aldosterone Nongenomically Produces NADPH Oxidase–Dependent Reactive Oxygen Species and Induces Myocyte Apoptosis , 2008, Hypertension Research.

[55]  Dana Dabelea,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[56]  W. Border,et al.  Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. , 2007, Kidney international.

[57]  K. Yee,et al.  Effect of spironolactone on C-reactive protein levels in patients with heart disease. , 2007, International journal of cardiology.

[58]  J. Huss,et al.  Mitochondrial energy metabolism in heart failure: a question of balance. , 2005, The Journal of clinical investigation.

[59]  Lie Gao,et al.  Superoxide Mediates Sympathoexcitation in Heart Failure: Roles of Angiotensin II and NAD(P)H Oxidase , 2004, Circulation research.

[60]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[61]  K. Nakao,et al.  Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. , 2004, Circulation.

[62]  J. Burnett,et al.  Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure , 2004, Circulation.

[63]  R. Paschke,et al.  Neurohumoral stimulation in type-2-diabetes as an emerging disease concept , 2004, Cardiovascular Diabetology.

[64]  E. Scott,et al.  Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension , 2003, Circulation.

[65]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[66]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[67]  K. Nakao,et al.  Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes , 2003, Circulation.

[68]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[69]  B. Lowell,et al.  βAR Signaling Required for Diet-Induced Thermogenesis and Obesity Resistance , 2002, Science.

[70]  K. Nakao,et al.  Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. , 2002, The Journal of clinical endocrinology and metabolism.

[71]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[72]  S. Anker,et al.  Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart Disease , 2002, Circulation.

[73]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[74]  E. Falkenstein,et al.  Nongenomic effects of aldosterone: cellular aspects and clinical implications , 2002, Steroids.

[75]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[76]  J. Keaney,et al.  Hydrogen Peroxide Activates Endothelial Nitric-oxide Synthase through Coordinated Phosphorylation and Dephosphorylation via a Phosphoinositide 3-Kinase-dependent Signaling Pathway* , 2002, The Journal of Biological Chemistry.

[77]  R. Nagai,et al.  Angiotensin II and Catecholamines Increase Plasma Levels of 8-Epi-Prostaglandin F2&agr; With Different Pressor Dependencies in Rats , 2002, Hypertension.

[78]  T. Meinertz,et al.  Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease , 2001, Circulation.

[79]  Y. Shen,et al.  Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[80]  KazuwaNakao,et al.  Aldosterone Production Is Activated in Failing Ventricle in Humans , 2001 .

[81]  W. Kübler,et al.  Endothelin-1 induces interleukin-6 release via acctivation of the transcription factor NF-κB in human vascular smooth muscle cells , 2000, Basic Research in Cardiology.

[82]  W. Daniel,et al.  Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. , 1999, Cardiovascular research.

[83]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[84]  R. Henning,et al.  Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. , 1999, Hypertension.

[85]  Daniel Levy,et al.  Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. , 1999, Circulation.

[86]  L. Orci,et al.  Regulation of fatty acid homeostasis in cells: novel role of leptin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Sanderson,et al.  Plasma brain natriuretic peptide — an independent predictor of cardiovascular mortality in acute heart failure , 1999, European journal of heart failure.

[88]  M. Redfield,et al.  Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[89]  E. Kraut,et al.  Myocardial ischemia in a patient with chronic refractory idiopathic thrombocytopenic purpura. , 1997, Archives of internal medicine.

[90]  D. Seals,et al.  Systemic hemodynamic determinants of blood pressure in women: age, physical activity, and hormone replacement. , 1997, The American journal of physiology.

[91]  B. Spiegelman,et al.  Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.

[92]  C. Gomez-Sanchez,et al.  Mechanisms of ET-1 potentiation of angiotensin II stimulation of aldosterone production. , 1993, The American journal of physiology.

[93]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[94]  C. Ferrario,et al.  In Vivo Metabolism of Angiotensin I by Neutral Endopeptidase (EC 3.4.24.11) in Spontaneously Hypertensive Rats , 1992, Hypertension.

[95]  K. Hosoda,et al.  Augmented secretion of brain natriuretic peptide in acute myocardial infarction. , 1991, Biochemical and biophysical research communications.

[96]  H. Imura,et al.  Hemodynamic, Renal, and Hormonal Responses to Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure , 1991, Circulation.

[97]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[98]  K. Nakao,et al.  Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. , 1990, Biochemical and biophysical research communications.

[99]  N. Minamino,et al.  Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits. , 1989, The American journal of physiology.

[100]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[101]  R. Anderson,et al.  Mechanism of renal potassium conservation in the rat. , 1979, Kidney international.

[102]  J. Bauer,et al.  Effect of potassium chloride on plasma renin activity and plasma aldosterone during sodium restriction in normal man. , 1979, Kidney international.

[103]  V. Murthy,et al.  A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. , 2013, Journal of the American College of Cardiology.

[104]  G. Merriam,et al.  Hypertension in Growth Hormone Excess and Deficiency , 2013 .

[105]  R. Rocha,et al.  Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure , 2012, Drugs.

[106]  S. Werns.  Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .

[107]  C. McTiernan,et al.  Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. , 2011, Cardiovascular research.

[108]  Circulation Editors’ Picks Most Read Articles in Hypertension the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy , 2022 .

[109]  M. Roizen.  General and Abdominal Adiposity and Risk of Death in Europe , 2009 .

[110]  R. Garrick.  Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy , 2009 .

[111]  J. Manson,et al.  Estrogen therapy and coronary-artery calcification. , 2007, The New England journal of medicine.

[112]  K. Weber,et al.  Aldosterone in Congestive Heart Failure , 2004 .

[113]  H. Krumholz,et al.  beta-Blocker therapy in heart failure: scientific review. , 2002, JAMA.

[114]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.

[115]  M. Pfeffer,et al.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.

[116]  T. Lüscher,et al.  Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. , 1997, Biochemical and biophysical research communications.

[117]  U. Vischer,et al.  Epinephrine Induces von Willebrand Factor Release from Cultured Endothelial Cells: Involvement of Cyclic AMP-dependent Signalling in Exocytosis , 1997, Thrombosis and Haemostasis.

[118]  R. Schade,et al.  Modulation of rat C-reactive protein serum level by dexamethasone and adrenaline--comparison with the response of alpha 2-acute phase globulin. , 1987, Agents and actions.

[119]  M. Drazner,et al.  Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Biomarker Substudy of the Surgical Treatment for Ischemic Heart Failure Trials , 2013, Circulation. Heart failure.